Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/23/2021 11/24/2021 11/25/2021 11/26/2021 11/29/2021 Date
707.4(c) 702.8(c) 716.4(c) 738.6(c) 732.8 Last
209 164 192 046 101 127 246 203 84 909 Volume
-4.69% -0.65% +1.94% +3.10% -0.79% Change
More quotes
Estimated financial data (e)
Sales 2021 5 174 M 5 591 M 5 591 M
Net income 2021 734 M 793 M 793 M
Net cash position 2021 569 M 615 M 615 M
P/E ratio 2021 74,5x
Yield 2021 0,41%
Sales 2022 5 879 M 6 353 M 6 353 M
Net income 2022 1 052 M 1 137 M 1 137 M
Net cash position 2022 491 M 531 M 531 M
P/E ratio 2022 51,9x
Yield 2022 0,45%
Capitalization 54 865 M 59 443 M 59 287 M
EV / Sales 2021 10,5x
EV / Sales 2022 9,25x
Nbr of Employees 14 405
Free-Float 99,7%
More Financials
Company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. 
More about the company
Ratings of Lonza Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about LONZA GROUP AG
01:33aOxford BioMedica, Lonza, Fujifilm Eye UK's Vaccine Manufacturing Innovation Center
MT
11/17Lonza Agrees to Manufacture Bluejay's Lead Antibody Candidate For Chronic Hepatitis B V..
MT
11/17GLOBAL MARKETS LIVE : Tesla, Experian, Roche, Activision, Amazon...
AX
11/17LONZA : and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778..
PU
11/16Lonza to Boost Microbial Development Lab Capabilities at Swiss Site
MT
11/16LONZA : to Expand Microbial Development Laboratories
PU
11/10Lonza JV Bacthera, Seres to Jointly Produce Potential Gut Infection Treatment
MT
11/05Cepsa explores chemicals sale to fund clean energy push - sources
RE
11/04AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Sell Recommendati..
MT
11/02Lonza to Buy Service Unit of Exosomics
MT
11/02Lonza Group to Purchase Specialized Manufacturing Plant From Codiak BioSciences
MT
11/02Lonza to Acquire Service Unit in Italy, Manufacturing Facility in US
DJ
11/02Lonza to Acquire Codiak BioSciences Exosome Manufacturing Plant
DJ
11/02Lonza to Acquire Exosomics Service Unit to Expand Exosomes Service Offering
PU
11/02Lonza Group Ltd agreed to acquire Service unit from Exosomics Siena S.p.A.
CI
More news
News in other languages on LONZA GROUP AG
11/26Aktien Schweiz knicken mit Corona-Ängsten ein - Logitech und Lonza fester
11/26Reise- und Luxusaktien gehen vor neuem Virus in die Knie
11/24Aktien Schweiz zur Wochenmitte mit moderaten Aufschlägen
11/23Aktien Schweiz schließen schwach - Partners Group sacken ab
11/19Aktien Schweiz schließen knapp behauptet - Logitech fest
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 738,60 CHF
Average target price 781,49 CHF
Spread / Average Target 5,81%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG29.85%59 443
MODERNA, INC.215.53%133 648
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548